Results 51 to 60 of about 23,381 (306)

Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat [PDF]

, 2018
OBJECTIVES: Pathogenesis of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is not fully explained. An antiangiogenic effect of bisphosphonates (BPs) or an altered bone quality have been advocated.
D. Chappard, F. Pascaretti-Grizon, G. Mabilleau, H. Marchand-Libouban, J.D. Kün-Darbois   +4 more
core   +1 more source

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw [PDF]

, 2017
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence of exposed bone in the oral cavity that persists for more than eight weeks.
Gaitán Cepeda, Luis Alberto, Gómez Clavel, José Francisco, Vidal Gutiérrez, Ximena   +2 more
core   +1 more source

The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey

BMC Oral Health, 2021
Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj   +1 more source

[A Case Report of Kampo Medicine Improving the Symptoms of Antiresorptive Agent-related Osteonecrosis of the Jaw (ARONJ)].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2021
A 56-year-old woman visited an oral surgery clinic in October X with sudden pain in the left mandible. She was diagnosed with left mandibular osteomyelitis based on head computed tomography examination findings.
Y. Yamazaki, M. Shimada
semanticscholar   +1 more source

Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma [PDF]

, 2015
Bone lytic lesion in Multiple myeloma are the most commonly presented symptoms which require treatment with bisphosphonates (BPs). BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria ...
Alan Archibald (45342), Aleksei Traspov (4453843), Alex Triantafyllidis (4453852), Bin Yang (103252), Christophe Knorr (4453837), DeodĂĄlia Dias (4453849), Gono Semiadi (2600656), Hendrik-Jan Megens (116285), Kesinee Gatphayak (4453840), Laura Iacolina (3249051), Lawrence Schook (131212), Leilei Cui (416135), Lusheng Huang (110011), Martien Groenen (3191614), Massimo Scandura (534340), Miguel Perez-Enciso (225658), Natalia Zinovieva (4453834), Olivier Hanotte (89422), Panoraia Alexandri (3245007), Pekka Uimari (463592), Peter Dovč (4453846), Richard Crooijmans (512752)   +21 more
core   +3 more sources

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Mandibular Osteonecrosis Associated with Antacid Therapy (Esomeprazole)

European Journal of Case Reports in Internal Medicine, 2019
Introduction: Osteonecrosis of the jaw has been consistently reported in the literature associated to the high-dose intravenous bisphosphonate therapy. However, osteonecrosis can also occur in patients who have other risk factors.
Simone Marconcini, Enrica Giammarinaro, Saverio Cosola, Anna Maria Genovesi, Ugo Covani   +4 more
doaj   +1 more source

Alendronate-Induced Osteonecrosis of the Jaw in an Elderly Female

International Journal of Gerontology, 2012
Background: In recent years, more and more evidence has demonstrated that a rare symptom, osteonecrosis of the jaw, may be associated with long-term use of bisphosphonates.
Bi-Wei Jan, Hui-Wen Liu, Hung Yu, Shen-Chuan Wang, Chung-Ji Liu   +4 more
doaj   +1 more source

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. [PDF]

, 2007
Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP) administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for i.v. administration), their efficacy
BADALAMENTI, Giuseppe, CAMPISI, Giuseppina, DI FEDE, Olga, FULFARO, Fabio, GEBBIA, Nicolo', LO CASTO, Antonio, LO MUZIO L, MUSCIOTTO, Anna, RUSSO, Antonio   +8 more
core   +1 more source

Drug-induced osteonecrosis of the jaw: the state of the art

Reumatismo, 2017
Osteonecrosis of the jaw (ONJ) is a rare adverse event of antiresorptive drugs such as bisphosphonates (BP) and denosumab (DMAb). The diagnosis of ONJ is considered in cases where exposed bone in the maxillofacial region does not heal within 8 weeks in a
A. Fassio, F. Bertoldo, L. Idolazzi, O. Viapiana, M. Rossini, D. Gatti   +5 more
doaj   +1 more source